Inventor · disambiguated record
Mark Mills
Also filed as: MILLS MARK · MILLS MARK TREVOR
13 granted patents·5 pending applications·19 citations·filing 2015–2024
87Inventor score
Files withCORCEPT THERAPEUTICS INC7KING S COLLEGE LONDON4ABBVIE INC2HEPTARES THERAPEUTICS LTD2CELGENE INT II SARL1
Top patents by PatentIndex Score
18 records- 0191US11787780B2Quaternary indazole glucocorticoid receptor antagonistsCORCEPT THERAPEUTICS INC·Filed 2021·Granted Oct 17, 2023·3 cites·28 claims
- 0288US10385044B2Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonistsKING S COLLEGE LONDON·Filed 2018·Granted Aug 20, 2019·6 cites·38 claims
- 0385US9994559B2Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonistsKING S COLLEGE LONDON·Filed 2015·Granted Jun 12, 2018·5 cites·30 claims
- 0483US11401265B2Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonistsKING S COLLEGE LONDON·Filed 2020·Granted Aug 2, 2022·1 cites·26 claims
- 0580US10752616B2Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonistsKING S COLLEGE LONDON·Filed 2019·Granted Aug 25, 2020·2 cites·28 claims
- 0678US2025214971A1Quaternary indazole glucocorticoid receptor antagonistsCORCEPT THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0777US12180186B2Quaternary indazole glucocorticoid receptor antagonistsCORCEPT THERAPEUTICS INC·Filed 2023·Granted Dec 31, 2024·0 cites·21 claims
- 0875US11993613B2Thiazolo[5,4-b]pyridine MALT-1 inhibitorsABBVIE INC·Filed 2023·Granted May 28, 2024·0 cites·2 claims
- 0974US2025115583A1Bicyclic indazole glucocorticoid receptor antagonistsCORCEPT THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1073US10034886B2GLP-1 receptor modulatorsCELGENE INT II SARL·Filed 2017·Granted Jul 31, 2018·1 cites·14 claims
- 1171US2025084099A1Thiazolo[5,4-b]pyridine malt-1 inhibitorsABBVIE INC·Filed 2024·Application pending·0 cites
- 1270US12098141B2Bicyclic indazole glucocorticoid receptor antagonistsCORCEPT THERAPEUTICS INC·Filed 2022·Granted Sep 24, 2024·0 cites·27 claims
- 1370US2025092023A1Piperazine indazole glucocorticoid receptor antagonistsCORCEPT THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1469US9795613B2GLP-1 receptor modulatorsCELGENE INT II SÀRL·Filed 2015·Granted Oct 24, 2017·1 cites·13 claims
- 1567US12098144B2Piperazine indazole glucocorticoid receptor antagonistsCORCEPT THERAPEUTICS INC·Filed 2022·Granted Sep 24, 2024·0 cites·28 claims
- 1665US12331029B2Orexin 1 receptor antagonistsNXERA PHARMA UK LTD·Filed 2019·Granted Jun 17, 2025·0 cites·17 claims
- 1752US12240825B2Oxexin 1 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Mar 4, 2025·0 cites·20 claims
- 1842US2021179578A1Ox1 antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Mills files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →